Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has shared an announcement.
Consun Pharmaceutical Group Limited announced that all resolutions proposed at its extraordinary general meeting held on 23 December 2025 were duly approved by shareholders by way of poll, with all directors attending in person or via video conference. Shareholders passed the adoption of a new share award scheme and a sublimit for service providers, as well as amendments to and a full restatement of the company’s Memorandum and Articles of Association, signaling board and investor alignment on revised incentive structures and updated corporate governance arrangements.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company engaged in the research, development and production of pharmaceutical products, with its shares traded on the Main Board of the Stock Exchange of Hong Kong under stock code 1681.
Average Trading Volume: 2,304,458
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.18B
See more insights into 1681 stock on TipRanks’ Stock Analysis page.